Spruce Biosciences, Inc.
SPRB
$0.0949
-$0.0349-26.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.91M | 7.10M | 9.57M | 10.13M | 10.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.91M | 7.10M | 9.57M | 10.13M | 10.09M |
| Cost of Revenue | 46.42M | 36.06M | 43.00M | 48.04M | 49.43M |
| Gross Profit | -41.51M | -28.96M | -33.43M | -37.91M | -39.34M |
| SG&A Expenses | 14.64M | 14.28M | 14.06M | 13.52M | 12.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.06M | 50.34M | 57.06M | 61.55M | 62.08M |
| Operating Income | -56.15M | -43.24M | -47.49M | -51.43M | -51.99M |
| Income Before Tax | -53.04M | -39.43M | -43.11M | -46.75M | -47.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.04 | -39.43 | -43.11 | -46.75 | -47.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.04M | -39.43M | -43.11M | -46.75M | -47.92M |
| EBIT | -56.15M | -43.24M | -47.49M | -51.43M | -51.99M |
| EBITDA | -56.11M | -43.19M | -47.43M | -51.36M | -51.92M |
| EPS Basic | -1.28 | -0.96 | -1.05 | -1.15 | -1.26 |
| Normalized Basic EPS | -0.80 | -0.60 | -0.66 | -0.72 | -0.79 |
| EPS Diluted | -1.28 | -0.96 | -1.05 | -1.15 | -1.26 |
| Normalized Diluted EPS | -0.80 | -0.60 | -0.66 | -0.72 | -0.79 |
| Average Basic Shares Outstanding | 165.06M | 164.35M | 163.76M | 163.14M | 153.94M |
| Average Diluted Shares Outstanding | 165.06M | 164.35M | 163.76M | 163.14M | 153.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |